SCHEMBL5865397

SCHEMBL5865397

CC(=O)ON1C(=O)c2ccc3c4c(ccc(c24)C1=O)C(=O)N(OC(C)=O)C3=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
PIN1 Q13526 1/20 0.43
PIN4 Q9Y237 1/20 0.43
KMT2A Q03164 4/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 3/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 5/20 0.38
APAF1 O14727 1/20 0.38
TERT O14746 3/20 0.36
LMNA P02545 2/20 0.36
PABPC1 P11940 2/20 0.36
HTT P42858 2/20 0.36
RGS12 O14924 1/20 0.36
RECQL P46063 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL859822 0.83 ALDH1A1 (0.47) KMT2AKDM4EALDH1A1MEN1HPGD
SCHEMBL29838651 0.83 ALDH1A1 (0.47) KMT2AKDM4EALDH1A1MEN1HPGD
SCHEMBL13814011 0.80 CA9 (0.49) KMT2AKDM4EALDH1A1HPGDPOLB
SCHEMBL5865650 0.79 PIN1 (0.51) NPC1RAB9AL3MBTL1PIN1PIN4
SCHEMBL859692 0.78 POLB (0.60) KMT2AKDM4EALDH1A1MEN1HPGD
SCHEMBL860092 0.78 ALDH1A1 (0.49) KMT2AALDH1A1HPGDHSD17B10POLB
SCHEMBL859502 0.76 ALDH1A1 (0.54) L3MBTL1KMT2AKDM4EALDH1A1MEN1
SCHEMBL8087968 0.76 ALDH1A1 (0.33) NPC1RAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL3684899 0.75 ALDH1A1 (0.56) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL13814012 0.75 ALDH1A1 (0.43) KMT2AKDM4EALDH1A1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1433527-B1 CATALYSTS COMPRISED OF N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS DAICEL CHEM (JP) 2013-11-06 EP disclosed
US-20060229196-A1 Catalyst comprising n-substituted cyclic imide compound and process for producing organic compounds using the catalyst ISHII YASUTAKA 2006-10-12 US disclosed
US-7084090-B2 Catalyst comprised of n-substituted cyclic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-08-01 US disclosed
EP-1433527-A1 CATALYSTS COMPRISED OF N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS Daicel Chemical Industries, Ltd. (JP) 2004-06-30 EP disclosed
US-20040053778-A1 Catalyst comprised of n-substituted cyclic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229196-A1 Catalyst comprising n-substituted cyclic imide compound and process for producing organic compounds using the catalyst NOS2, NOS1, NOS3 NPC1 3823/4885RAB9A 3062/4885L3MBTL1 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.